Clinical experience with substance P receptor (NK1) antagonists in depression

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 11, 2002, Pages 25-29

  Krishnan, K Ranga R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; NEUROKININ; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NEUROTRANSMITTER; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P ANTAGONIST;

ANXIETY DISORDER; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; CLINICAL MEDICINE; CLINICAL TRIAL; DEPRESSION; DOSE CALCULATION; HUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHERS; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MORPHOLINES; PAROXETINE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, NEUROKININ-1; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUBSTANCE P; TREATMENT OUTCOME;

EID: 0036452950     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. National Institutes of Health. Invisible Disease: Depression. Bethesda, Md: National Institutes of Health; 2001. NIH publication 01-4591
2. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
3. Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and adolescents: An epidemiologic perspective. Biol Psychiatry 2001;49:1002-1014
4. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999;20:485-490
5. Saria A. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions. Eur J Pharmacol 1999;375:51-60
6. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-1645
7. Rupniak NM, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000;39:1413-1421
8. Rimon R, Le Greves P, Nyberg F, et al. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984;19:509-516
9. Berrettini WH, Rubinow DR, Numberger JI Jr, et al. CSF substance P immunoreactivity in affective disorders. Biol Psychiatry 1985;20:965-970
10. Rupniak NM, Williams AR. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol 1994;265:179-183
11. Kramer MS. Substance P (NK1) receptor antagonists (SPAs) in patients with major depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii